Cancer Metastases: Challenges and Opportunities

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2015 Nov 19

PMID 26579471

Citations 416

Authors

Xiangming Guan

Affiliations

Soon will be listed here.

Abstract

Cancer metastasis is the major cause of cancer morbidity and mortality, and accounts for about 90% of cancer deaths. Although cancer survival rate has been significantly improved over the years, the improvement is primarily due to early diagnosis and cancer growth inhibition. Limited progress has been made in the treatment of cancer metastasis due to various factors. Current treatments for cancer metastasis are mainly chemotherapy and radiotherapy, though the new generation anti-cancer drugs (predominantly neutralizing antibodies for growth factors and small molecule kinase inhibitors) do have the effects on cancer metastasis in addition to their effects on cancer growth. Cancer metastasis begins with detachment of metastatic cells from the primary tumor, travel of the cells to different sites through blood/lymphatic vessels, settlement and growth of the cells at a distal site. During the process, metastatic cells go through detachment, migration, invasion and adhesion. These four essential, metastatic steps are inter-related and affected by multi-biochemical events and parameters. Additionally, it is known that tumor microenvironment (such as extracellular matrix structure, growth factors, chemokines, matrix metalloproteinases) plays a significant role in cancer metastasis. The biochemical events and parameters involved in the metastatic process and tumor microenvironment have been targeted or can be potential targets for metastasis prevention and inhibition. This review provides an overview of these metastasis essential steps, related biochemical factors, and targets for intervention.

Citing Articles

The Combined Assessment of CTC and Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer.

Szostakowska-Rodzos M, Grzybowska E, Mysliwy I, Zub R, Jagiello-Gruszfeld A, Rubach M Int J Mol Sci. 2025; 26(5).

PMID: 40076662 PMC: 11900918. DOI: 10.3390/ijms26052038.

Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.

Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T Biomark Res. 2025; 13(1):38.

PMID: 40045379 PMC: 11884212. DOI: 10.1186/s40364-025-00745-7.

Metastatic Melanoma Treatment and Prophylaxis with S100A9-Targeting Cowpea Mosaic Virus Nanoparticles.

Chung Y, Steinmetz N Methods Mol Biol. 2025; 2902:13-36.

PMID: 40029594 DOI: 10.1007/978-1-0716-4402-7_2.

Nanomechanical characterization of soft nanomaterial using atomic force microscopy.

Lam C, Park S Mater Today Bio. 2025; 31:101506.

PMID: 40018054 PMC: 11867545. DOI: 10.1016/j.mtbio.2025.101506.

Unveiling the effects of GSK126 on osteosarcoma cells implications for apoptosis, autophagy, and cellular migration.

Xiong X, Liu Y, Du Y, Lai X, Si C, Miao H Discov Oncol. 2025; 16(1):245.

PMID: 40014170 PMC: 11868014. DOI: 10.1007/s12672-025-02010-7.

References

McAllister S, Weinberg R . The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014; 16(8):717-27. PMC: 6220424. DOI: 10.1038/ncb3015. View

Zanotti S, Gibertini S, Bragato C, Mantegazza R, Morandi L, Mora M . Fibroblasts from the muscles of Duchenne muscular dystrophy patients are resistant to cell detachment apoptosis. Exp Cell Res. 2011; 317(17):2536-47. DOI: 10.1016/j.yexcr.2011.08.004. View

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso M . Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014; 2014:149185. PMC: 4036716. DOI: 10.1155/2014/149185. View

Janik M, Litynska A, Vereecken P . Cell migration-the role of integrin glycosylation. Biochim Biophys Acta. 2010; 1800(6):545-55. DOI: 10.1016/j.bbagen.2010.03.013. View

Wong C, Dye D, Coombe D . The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol. 2012; 2012:340296. PMC: 3261479. DOI: 10.1155/2012/340296. View

Sakamoto S, Kyprianou N . Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med. 2010; 31(2):205-14. PMC: 2988681. DOI: 10.1016/j.mam.2010.02.001. View

Lokeshwar V, Bourguignon L . Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J Biol Chem. 1991; 266(27):17983-9. View

Roland C, Harken A, Sarr M, Barnett Jr C . ICAM-1 expression determines malignant potential of cancer. Surgery. 2007; 141(6):705-7. DOI: 10.1016/j.surg.2007.01.016. View

Buchheit C, Weigel K, Schafer Z . Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014; 14(9):632-41. DOI: 10.1038/nrc3789. View

10.

Deryugina E, Bourdon M, Luo G, Reisfeld R, Strongin A . Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci. 1997; 110 ( Pt 19):2473-82. DOI: 10.1242/jcs.110.19.2473. View

11.

Omidi Y, Barar J . Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts. 2014; 4(2):55-67. PMC: 4097973. DOI: 10.5681/bi.2014.021. View

12.

Richter U, Wicklein D, Geleff S, Schumacher U . The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012; 137(5):687-95. DOI: 10.1007/s00418-012-0916-5. View

13.

Wood S, Pernemalm M, Crosbie P, Whetton A . The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2013; 40(4):558-66. DOI: 10.1016/j.ctrv.2013.10.001. View

14.

Blaschuk O, Sullivan R, David S, Pouliot Y . Identification of a cadherin cell adhesion recognition sequence. Dev Biol. 1990; 139(1):227-9. DOI: 10.1016/0012-1606(90)90290-y. View

15.

Alva A, Slovin S, Daignault S, Carducci M, DiPaola R, Pienta K . Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2010; 30(2):749-57. PMC: 3175265. DOI: 10.1007/s10637-010-9573-5. View

16.

Spano D, Heck C, De Antonellis P, Christofori G, Zollo M . Molecular networks that regulate cancer metastasis. Semin Cancer Biol. 2012; 22(3):234-49. DOI: 10.1016/j.semcancer.2012.03.006. View

17.

Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D . Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013; 34(5):283-9. PMC: 3640670. DOI: 10.1016/j.tips.2013.03.001. View

18.

Wolf K, Friedl P . Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis. 2008; 26(4):289-98. DOI: 10.1007/s10585-008-9190-2. View

19.

Siesser P, Maness P . L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adh Migr. 2009; 3(3):275-7. PMC: 2712809. DOI: 10.4161/cam.3.3.8689. View

20.

Shuman Moss L, Jensen-Taubman S, Stetler-Stevenson W . Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol. 2012; 181(6):1895-9. PMC: 3506216. DOI: 10.1016/j.ajpath.2012.08.044. View